Expense

EQS-News: Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Wednesday, March 13, 2024

The highly encouraging results demonstrated clear separation from placebo in serum neurofilament light chain (NfL) levels in patients with progressive multiple sclerosis (PMS).

Key Points: 
  • The highly encouraging results demonstrated clear separation from placebo in serum neurofilament light chain (NfL) levels in patients with progressive multiple sclerosis (PMS).
  • The results demonstrated meaningful improvements over placebo in four key dimensions of celiac disease pathophysiology: histology, disease symptoms, biomarkers and nutrient absorption.
  • Registrants will receive a confirmation email containing a link for online participation or a telephone number for dial in access.
  • An archived replay of the webcast will be available approximately one hour after completion on Immunic’s website at: ir.imux.com/events-and-presentations .

YieldMax™ Launches the Ultra Option Income Strategy ETF ULTY

Retrieved on: 
Thursday, February 29, 2024

1 All YieldMax™ ETFs shown in the table above (except YMAX and YMAG) have a gross expense ratio of 0.99%.

Key Points: 
  • 1 All YieldMax™ ETFs shown in the table above (except YMAX and YMAG) have a gross expense ratio of 0.99%.
  • The Distribution Rate is the annual yield an investor would receive if the most recently declared distribution, which includes option income, remained the same going forward.
  • The Distribution Rate represents a single distribution from the ETF and does not represent its total return.
  • Such potential losses may not be offset by income received by the ETF.

YieldMax™ Launches Option Income Strategy ETF on MicroStrategy (MSTR)

Retrieved on: 
Thursday, February 22, 2024

The Distribution Rate is the annual yield an investor would receive if the most recently declared distribution, which includes option income, remained the same going forward.

Key Points: 
  • The Distribution Rate is the annual yield an investor would receive if the most recently declared distribution, which includes option income, remained the same going forward.
  • The Distribution Rate represents a single distribution from the ETF and does not represent its total return.
  • 3 The 30-Day SEC Yield represents net investment income, which excludes option income, earned by such ETF over the 30-Day period ended January 31, 2024, expressed as an annual percentage rate based on such ETF’s share price at the end of the 30-Day period.
  • Such potential losses may not be offset by income received by the ETF.

Lineage Cell Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 7, 2024

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.

Key Points: 
  • Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported its fourth quarter and full year 2023 financial and operating results and will host a conference call today at 4:30 p.m. Eastern Time to discuss these results and provide a business update.
  • “Throughout 2023, our team has continued to advance our clinical and preclinical pipeline of differentiated cell transplant programs,” stated Brian M. Culley, Lineage CEO.
  • Long-term follow-up of patients from the Phase 1/2a clinical study of OpRegen:
    Positive clinical data presented at 2023 Eyecelerator , 23rd EU RETINA Congress , and 2023 ARVO Annual Meetings.
  • Initiated development activities for hypoimmune pluripotent cell line for neurology indications under collaboration with Eterna Therapeutics.

Kontoor Brands Reports 2023 Fourth Quarter and Full Year Results; Provides 2024 Outlook and Announces Project Jeanius Global Transformation

Retrieved on: 
Wednesday, February 28, 2024

“Our POS performance in the U.S. outpaced shipments in the fourth quarter and resulted in continued market share gains.

Key Points: 
  • “Our POS performance in the U.S. outpaced shipments in the fourth quarter and resulted in continued market share gains.
  • Selling, General & Administrative (SG&A) expenses were $204 million or 30.5 percent of revenue on a reported basis in the fourth quarter.
  • The Company anticipates the impact from Project Jeanius to begin in the fourth quarter of 2024, with more significant benefits expected in 2025 and 2026.
  • Kontoor Brands will host its fourth quarter and full year 2023 conference call beginning at 8:30 a.m. Eastern Time today, February 28, 2024.

Eighth Annual State of the Data Center Industry Report Reveals How Power Design and AI Demand Has Forever Changed the Industry

Retrieved on: 
Tuesday, February 20, 2024

AFCOM , the leading membership association for data center professionals, and Data Center World , the leading global conference for data center facilities and IT professionals, today announce the results of the eighth annual State of the Data Center industry report.

Key Points: 
  • AFCOM , the leading membership association for data center professionals, and Data Center World , the leading global conference for data center facilities and IT professionals, today announce the results of the eighth annual State of the Data Center industry report.
  • The report, which has been a fixture at the annual Data Center World industry conference, continues to capture the relentless pace of change in the data center industry.
  • As AI requirements grow, there has been a significant surge in demand, with a mounting focus on capacity to meet higher-density data center requirements.
  • Data Center World 2024 takes place April 15-18 in Washington, D.C. To register to attend Data Center World, click here .

Federal Home Loan Bank of Des Moines Announces 2023 Fourth Quarter and Annual Results, Declares Dividend

Retrieved on: 
Friday, February 16, 2024

In addition, the Bank increased its activity stock requirement on advances from 4.00 percent to 4.50 percent.

Key Points: 
  • In addition, the Bank increased its activity stock requirement on advances from 4.00 percent to 4.50 percent.
  • The Board of Directors approved a fourth quarter 2023 dividend to be paid at an annualized rate of 9.00 percent on average activity-based stock, an increase of 0.50 percent from the prior quarter, and 3.55 percent on average membership stock, an increase of 0.55 percent from the prior quarter.
  • Dividend payments totaling $136 million are expected to be paid on February 23, 2024.
  • Net Income - The Bank recorded net income of $962 million in 2023 compared to $430 million in the prior year.

YieldMax™ ETFs Announces Monthly Distributions on Fund of Funds ETFs

Retrieved on: 
Wednesday, February 14, 2024

“Acquired Fund Fees and Expenses” are indirect fees and expenses that the Fund incurs from investing in the shares of other investment companies, namely other YieldMax™ ETFs.

Key Points: 
  • “Acquired Fund Fees and Expenses” are indirect fees and expenses that the Fund incurs from investing in the shares of other investment companies, namely other YieldMax™ ETFs.
  • The Distribution Rate and 30-Day SEC Yield are not indicative of future distributions, if any, on the ETFs.
  • Distributions for the ETFs (if any) are variable and may vary significantly from month to month and may be zero.
  • The repetitive payment of distributions may significantly erode an Underlying YieldMax™ ETF’s NAV and trading price over time, potentially resulting in notable losses for investors (including the Fund).

CNH Industrial N.V. Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Wednesday, February 14, 2024

CNH is continuing its efforts to improve through-cycle margins with its two previously announced cost reduction programs.

Key Points: 
  • CNH is continuing its efforts to improve through-cycle margins with its two previously announced cost reduction programs.
  • The second program is focused on restructuring SG&A expenses and was announced in conjunction with Q3 2023 earnings.
  • CNH reports quarterly and annual consolidated financial results under U.S. GAAP and EU-IFRS.
  • Adjusted EBIT Margin of Industrial Activities: is computed by dividing Adjusted EBIT of Industrial Activities by Net Sales of Industrial Activities.

PetVivo Reports Third Quarter of Fiscal 2024 Financial Results

Retrieved on: 
Monday, February 12, 2024

EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended December 31, 2023 (“third quarter of 2024”).

Key Points: 
  • Conference call begins at 4:00 p.m. Central time today
    EDINA, MN, Feb. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (Nasdaq: PETV), an emerging biomedical device company focused on the commercialization of innovative medical therapeutics for animals, announces financial results for the three months ended December 31, 2023 (“third quarter of 2024”).
  • “We are excited about the progress the Company has made this past quarter, including the addition of Covetrus North America, LLC.
  • (Covetrus), to distribute our products beginning in January 2024,” said John Lai, Chief Executive Officer of PetVivo Holdings, Inc.
  • Cost of sales were $183,087 and $223,687 for the three months ended December 31, 2023 and 2022, respectively.